Bioavailability refers to the amount of a nutrient that actually enters your circulation and is able to have an active effect
Adverse Events Across Trials The safety pattern is consistent across the published trials: gastrointestinal events dominate, they are dose-related, mostly mild to moderate, concentrated during dose escalation, and partially mitigated by starting at 2 mg rather than 4 mg
Because gastrointestinal effects are dose-related, gradual titration helps improve tolerability
This can happen if someone is born with one kidney (renal agenesis), has one removed due to illness or injury (nephrectomy), or has donated a kidney to someone else
Hydrocortisone 1% cream applied to site (not at injection moment, but after)
Heres a brief history of GLP-1 agonists: Discovery of GLP-1: GLP-1 was first discovered in the early 1980s